38th Annual Miami Breast Cancer Conference® - Abstracts

1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population

April 30th 2021

6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood

April 30th 2021

7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer

April 30th 2021

8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice

April 30th 2021

13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis

April 30th 2021

14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network

April 30th 2021

25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors

April 30th 2021

28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer

April 30th 2021

30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide

April 30th 2021

35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line

April 30th 2021

37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women

April 30th 2021

42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib

April 30th 2021

43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis

April 30th 2021

44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer

April 30th 2021

45 Neoadjuvant Chemotherapy Use in Elderly Patients

April 30th 2021

56 A Phase 2 Exploratory Study of Intravenous Cetirizine Versus Intravenous Diphenhydramine in the Prevention of Hypersensitivity Infusion Reactions in Patients With Breast Cancer and Other Malignancies

April 30th 2021

5 A Prospective, Double-Blinded, Randomized Controlled Trial Comparing the Intraoperative Injection of Technetium Tc 99m Tilmanocept With Technetium Tc 99m Sulfur Colloid in Breast Cancer Lymphatic Mapping

April 30th 2021

9 Comparison of Immediate Breast Reconstruction Outcomes in Patients With and Without Prior Breast Cosmetic Surgical Procedures

April 30th 2021

11 Do Breast Surgeons Play an Important Role in a Clinic for Benign Breast Disease?

April 30th 2021

12 Caseload of Rural General Surgeons: A Focus on Breast Surgery

April 30th 2021

17 TiP The Treatment of Breast Cancer With Percutaneous Thermal Ablation: A Phase 2 Screening Trial

April 30th 2021

18 The Impact on Management and Outcomes of Benign and High-Risk Breast Lesions After the Introduction of Vacuum-Assisted Excision

April 29th 2021

20 Assessment of Textbook Oncologic Outcomes Following Modified Radical Mastectomy for Invasive Ductal Carcinoma: A Review of the 2004-2017 National Cancer Database

April 29th 2021

27 Radar Reflector Localization of Peripheral Nonpalpable Lesions During Skin-Sparing and Nipple-Sparing Mastectomy: A Novel Application Using the IDEAL Framework

April 29th 2021

40 Objective Comparison of Postoperative Activity After Sentinel Lymph Node Biopsy vs Axillary Node Clearance Using Wearable Activity Monitors

April 29th 2021

41 Pathologic Complete Response (pCR) Rates According to MammaPrint and BluePrint Test Results Are Consistent Among Pre and Postmenopausal Patients

April 29th 2021

49 Registry Study of a Nonpalpable Verifiable Filament Marker of the Breast Tumor Bed

April 29th 2021

50 Breast Tissue Differentiation With High Wavenumber Raman Spectroscopy for Future Intraoperative Margin Analysis

April 29th 2021

51 Institution Case Study Series With Tc-99m Tilmanocept for Efficiencies in Sentinel Lymph Node Biopsy

April 29th 2021

38th Annual Miami Breast Cancer Conference® - Abstracts

1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population

6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood

7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer

8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice

13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis

14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network

25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors

28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer

30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide

35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line

37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women

42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib

43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis

44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer

45 Neoadjuvant Chemotherapy Use in Elderly Patients

56 A Phase 2 Exploratory Study of Intravenous Cetirizine Versus Intravenous Diphenhydramine in the Prevention of Hypersensitivity Infusion Reactions in Patients With Breast Cancer and Other Malignancies

5 A Prospective, Double-Blinded, Randomized Controlled Trial Comparing the Intraoperative Injection of Technetium Tc 99m Tilmanocept With Technetium Tc 99m Sulfur Colloid in Breast Cancer Lymphatic Mapping

9 Comparison of Immediate Breast Reconstruction Outcomes in Patients With and Without Prior Breast Cosmetic Surgical Procedures

11 Do Breast Surgeons Play an Important Role in a Clinic for Benign Breast Disease?

12 Caseload of Rural General Surgeons: A Focus on Breast Surgery

17 TiP The Treatment of Breast Cancer With Percutaneous Thermal Ablation: A Phase 2 Screening Trial

18 The Impact on Management and Outcomes of Benign and High-Risk Breast Lesions After the Introduction of Vacuum-Assisted Excision

20 Assessment of Textbook Oncologic Outcomes Following Modified Radical Mastectomy for Invasive Ductal Carcinoma: A Review of the 2004-2017 National Cancer Database

27 Radar Reflector Localization of Peripheral Nonpalpable Lesions During Skin-Sparing and Nipple-Sparing Mastectomy: A Novel Application Using the IDEAL Framework

40 Objective Comparison of Postoperative Activity After Sentinel Lymph Node Biopsy vs Axillary Node Clearance Using Wearable Activity Monitors

41 Pathologic Complete Response (pCR) Rates According to MammaPrint and BluePrint Test Results Are Consistent Among Pre and Postmenopausal Patients

49 Registry Study of a Nonpalpable Verifiable Filament Marker of the Breast Tumor Bed

50 Breast Tissue Differentiation With High Wavenumber Raman Spectroscopy for Future Intraoperative Margin Analysis

51 Institution Case Study Series With Tc-99m Tilmanocept for Efficiencies in Sentinel Lymph Node Biopsy

4 Incidental Breast Cancer on Chest CT: Is the Radiology Report Enough?

Trending on CancerNetwork

ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care

How Should a Patient With Multiple Myeloma Manage Talquetamab’s Toxicity?

FDA Approves Niraparib Regimen in BRCA2+ Metastatic CSPC

EMD Associated With Poorer Outcomes in Previously Treated R/R Multiple Myeloma

Pre-Cevostamab Treatment May Not Impact Outcomes as Much in Multiple Myeloma